Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
Bazydlo-Guzenda K, Buda P, Matloka M, Mach M, Stelmach F, Dzida R, Smuga D, Hucz-Kalitowska J, Teska-Kaminska M, Vialichka V, Dubiel K, Kaminska B, Wieczorek M, Pieczykolan J. Bazydlo-Guzenda K, et al. Among authors: buda p. Mol Pharmacol. 2021 Oct;100(4):335-347. doi: 10.1124/molpharm.121.000260. Epub 2021 Aug 4. Mol Pharmacol. 2021. PMID: 34349026
Discovery and development of CPL207280 as new GPR40/FFA1 agonist.
Mach M, Bazydło-Guzenda K, Buda P, Matłoka M, Dzida R, Stelmach F, Gałązka K, Wąsińska-Kałwa M, Smuga D, Hołowińska D, Dawid U, Gurba-Bryśkiewicz L, Wiśniewski K, Dubiel K, Pieczykolan J, Wieczorek M. Mach M, et al. Among authors: buda p. Eur J Med Chem. 2021 Dec 15;226:113810. doi: 10.1016/j.ejmech.2021.113810. Epub 2021 Sep 1. Eur J Med Chem. 2021. PMID: 34537444
First-in-human study of CPL207280, a novel G-protein-coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration.
Bazydło-Guzenda K, Jarus-Dziedzic K, Gierczak-Pachulska A, Buda P, Rudzki PJ, Buś-Kwaśnik K, Juszczyk E, Tratkiewicz E, Rabczenko D, Segiet-Święcicka A, Wieczorek M. Bazydło-Guzenda K, et al. Among authors: buda p. Diabetes Obes Metab. 2024 Apr;26(4):1376-1385. doi: 10.1111/dom.15439. Epub 2024 Jan 11. Diabetes Obes Metab. 2024. PMID: 38204407
The complement inhibitor CD59 regulates insulin secretion by modulating exocytotic events.
Krus U, King BC, Nagaraj V, Gandasi NR, Sjölander J, Buda P, Garcia-Vaz E, Gomez MF, Ottosson-Laakso E, Storm P, Fex M, Vikman P, Zhang E, Barg S, Blom AM, Renström E. Krus U, et al. Among authors: buda p. Cell Metab. 2014 May 6;19(5):883-90. doi: 10.1016/j.cmet.2014.03.001. Epub 2014 Apr 10. Cell Metab. 2014. PMID: 24726385 Free article.
FCGR2/3 polymorphisms are associated with susceptibility to Kawasaki disease but do not predict intravenous immunoglobulin resistance and coronary artery aneurysms.
Uittenbogaard P, Netea SA, Tanck MWT, Geissler J, Buda P, Kowalczyk-Domagała M, Okarska-Napierała M, van Stijn D, Tacke CE; US Kawasaki Disease Genetics Consortium; Burgner DP, Shimizu C, Burns JC, Kuipers IM, Kuijpers TW, Nagelkerke SQ. Uittenbogaard P, et al. Among authors: buda p. Front Immunol. 2024 Sep 18;15:1323171. doi: 10.3389/fimmu.2024.1323171. eCollection 2024. Front Immunol. 2024. PMID: 39359734 Free PMC article.
51 results